Potential of improving the treatment of tuberculosis through nanomedicine

Boitumelo Semete; Lonji Kalombo; Lebogang Katata; Paul Chelule; Laetitia Booysen; Yolandy Lemmer; Saloshnee Naidoo; Bathabile Ramalapa; Rose Hayeshi; Hulda S. Swai

doi:10.1080/15421406.2012.635531

Potential of improving the treatment of tuberculosis through nanomedicine

Boitumelo Semete
, Lonji Kalombo
, Lebogang Katata
, Paul Chelule
, Laetitia Booysen
, Yolandy Lemmer
, Saloshnee Naidoo
, Bathabile Ramalapa
, Rose Hayeshi
, Hulda S. Swai

Research output: Contribution to conference › Paper

7 Citations (Scopus)

Abstract

Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single dose that maintains an active level of drug for at least a week. Polymeric poly(lactic-co-glycolic acid) nanoparticles of 200-300 nm were synthesized, with a drug encapsulation efficiency of 50-65% for isoniazid and rifampicin. The particles were taken up in vitro and in vivo and a slow release profile was observed in mice over 5 days. This study illustrates the feasibility of a sustained release system for tuberculosis treatment. © Taylor & Francis Group, LLC.

Original language	English
Pages	317-330
Number of pages	14
DOIs	https://doi.org/10.1080/15421406.2012.635531
Publication status	Published - 1 Jun 2012
Externally published	Yes
Event	Molecular Crystals and Liquid Crystals - Duration: 1 Jun 2012 → …

Conference

Conference	Molecular Crystals and Liquid Crystals
Period	01/Jun/12 → …

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1080/15421406.2012.635531

Cite this

@conference{cafdd962077b4082b94fb4a440914826,

title = "Potential of improving the treatment of tuberculosis through nanomedicine",

abstract = "Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single dose that maintains an active level of drug for at least a week. Polymeric poly(lactic-co-glycolic acid) nanoparticles of 200-300 nm were synthesized, with a drug encapsulation efficiency of 50-65\% for isoniazid and rifampicin. The particles were taken up in vitro and in vivo and a slow release profile was observed in mice over 5 days. This study illustrates the feasibility of a sustained release system for tuberculosis treatment. {\textcopyright} Taylor \& Francis Group, LLC.",

author = "Boitumelo Semete and Lonji Kalombo and Lebogang Katata and Paul Chelule and Laetitia Booysen and Yolandy Lemmer and Saloshnee Naidoo and Bathabile Ramalapa and Rose Hayeshi and Swai, \{Hulda S.\}",

year = "2012",

month = jun,

day = "1",

doi = "10.1080/15421406.2012.635531",

language = "English",

pages = "317--330",

note = "Molecular Crystals and Liquid Crystals ; Conference date: 01-06-2012",

}

TY - CONF

T1 - Potential of improving the treatment of tuberculosis through nanomedicine

AU - Semete, Boitumelo

AU - Kalombo, Lonji

AU - Katata, Lebogang

AU - Chelule, Paul

AU - Booysen, Laetitia

AU - Lemmer, Yolandy

AU - Naidoo, Saloshnee

AU - Ramalapa, Bathabile

AU - Hayeshi, Rose

AU - Swai, Hulda S.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single dose that maintains an active level of drug for at least a week. Polymeric poly(lactic-co-glycolic acid) nanoparticles of 200-300 nm were synthesized, with a drug encapsulation efficiency of 50-65% for isoniazid and rifampicin. The particles were taken up in vitro and in vivo and a slow release profile was observed in mice over 5 days. This study illustrates the feasibility of a sustained release system for tuberculosis treatment. © Taylor & Francis Group, LLC.

AB - Current treatment of tuberculosis is inadequate due to lengthy treatment course and drug-related toxicity. To address these setbacks, we developed a nanotechnology drug delivery system that can be administered in a single dose that maintains an active level of drug for at least a week. Polymeric poly(lactic-co-glycolic acid) nanoparticles of 200-300 nm were synthesized, with a drug encapsulation efficiency of 50-65% for isoniazid and rifampicin. The particles were taken up in vitro and in vivo and a slow release profile was observed in mice over 5 days. This study illustrates the feasibility of a sustained release system for tuberculosis treatment. © Taylor & Francis Group, LLC.

UR - https://www.scopus.com/pages/publications/84861548021

UR - https://www.scopus.com/pages/publications/84861548021#tab=citedBy

U2 - 10.1080/15421406.2012.635531

DO - 10.1080/15421406.2012.635531

M3 - Paper

SP - 317

EP - 330

T2 - Molecular Crystals and Liquid Crystals

Y2 - 1 June 2012

ER -

Potential of improving the treatment of tuberculosis through nanomedicine

Abstract

Conference

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this